The ability of immune cells—particularly CD8 + T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Three days post viral infection CD8 T cells (red) re-arrest with antigen presenting cells (cyan), where they are supplied with IL-2 by CD4 T cells (yellow), which migrate in a stop and go pattern. The ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Clonally expanded CD8+ T cells are key drivers of alopecia areata, mediating epithelial cell death and immune infiltration. JAK inhibitors are approved for AA treatment, but recurrence is common, ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...

WEHI scientists have uncovered a promising new way to enhance the effectiveness of vaccines by tapping into the potential of a specific type of immune cell, opening the door to long-lasting vaccines ...